Journal article icon

Journal article

Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia.

Abstract:

BACKGROUND: The Bowman-Birk inhibitor is a soybean-derived protease inhibitor that has anti-inflammatory and anticarcinogenic activities. METHODS: A Phase I trial of Bowman-Birk inhibitor concentrate (BBIC) in 19 male subjects with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) has been performed. RESULTS: The results of the trial indicated that there was no dose-limiting toxicity of BBIC. There was a statistically significant decrease in serum PSA levels in all BB...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/pros.1077

Authors


Malkowicz, SB More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Vaughn, DJ More by this author
Propert, KJ More by this author
Expand authors...
Journal:
The Prostate
Volume:
48
Issue:
1
Pages:
16-28
Publication date:
2001-06-05
DOI:
EISSN:
1097-0045
ISSN:
0270-4137
URN:
uuid:2cf73bb1-b0a7-4920-84da-7005e13d712a
Source identifiers:
118180
Local pid:
pubs:118180

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP